NCT06798506View on ClinicalTrials.gov

Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer

Not yet recruitingOBSERVATIONAL

Enrollment

300

Participants

Timeline

Start Date

February 15, 2025

Primary Completion Date

January 15, 2027

Study Completion Date

May 15, 2027

Conditions

TNBC - Triple-Negative Breast Cancer

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER